Abstract
Wilson’s disease (WD) is characterized by the inability to excrete copper (Cu) from the body with progressive tissue injury, especially in liver and brain. The molecular defect in WD concerns mutations in ATP7B gene leading to loss of Cu transport from the hepatocyte to the bile canaliculus. While drugs, e.g., Cu chelators, have been available for several decades, these must be taken lifelong, which can be difficult due to issues of compliance or side effects. Many individuals may require liver transplantation, which can also be difficult due to donor organ shortages. Therefore, achieving permanent cures via cell or gene therapy are of great interest for WD. Cell therapy is feasible because transplanted hepatocytes can integrate in liver parenchyma and restore deficient functions, including transport of Cu into bile. The availability of authentic animal models that recapitulate hepatic WD, especially the Long-Evans Cinnamon (LEC) rat, has advanced cell transplantation research in WD. We describe requirements for cell therapy in animal models with several standardized methods for studies to test or refine cell therapy strategies in WD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW (2014) The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 5:327–337
Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML (2007) Wilson’s disease. Lancet 369:397–408
Kim BE, Nevitt T, Thiele DJ (2008) Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 4:176–185
Weiss KH, Schäfer M, Gotthardt DN, Angerer A, Mogler C, Schirmacher P, Schemmer P, Stremmel W, Sauer P (2013) Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. Clin Transplant 27:914–922
Gupta S (2014) Cell therapy to remove excess copper in Wilson’s disease. Ann NY Acad Sci 1315:70–80
Bandi S, Joseph B, Berishvili E, Singhania R, Wu YM, Cheng K, Gupta S (2011) Perturbations in ataxia telangiectasia mutant signaling pathways after drug-induced acute liver failure and their reversal during rescue of animals by cell therapy. Am J Pathol 178:161–174
Hansel MC, Gramignoli R, Skvorak KJ, Dorko K, Marongiu F, Blake W, Davila J, Strom SC (2014) The history and use of human hepatocytes for the treatment of liver diseases: the first 100 patients. Curr Protoc Toxicol 12:1–23
Gramignoli R, Vosough M, Kannisto K, Srinivasan RC, Strom SC (2015) Clinical hepatocyte transplantation: practical limits and possible solutions. Eur Surg Res 54:162–177
Viswanathan P, Kapoor S, Kumaran V, Joseph B, Gupta S (2014) Etanercept blocks inflammatory responses orchestrated by TNF-α to promote transplanted cell engraftment and proliferation in rat liver. Hepatology 60:1378–1388
Malhi H, Irani AN, Volenberg I, Schilsky ML, Gupta S (2002) Early cell transplantation in LEC rats modeling Wilson's disease eliminates hepatic copper with reversal of liver disease. Gastroenterology 122:438–447
Malhi H, Joseph B, Schilsky ML, Gupta S (2008) Development of cell therapy strategies to overcome copper toxicity in the LEC rat model of Wilson disease. Regen Med 3:165–173
Joseph B, Kapoor S, Schilsky ML, Gupta S (2009) Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the LEC rat model. Hepatology 49:1616–1624
Bahde R, Kapoor S, Bhargava KK, Schilsky ML, Palestro CJ, Gupta S (2012) Positron emission tomography with copper-64-histidine for nonivasive diagnosis of biliary copper excretion in LEC rat model of Wilson’s disease. J Nucl Med 53:961–968
Peng F, Lutsenko S, Sun X, Muzik O (2012) Positron emission tomography of copper metabolism in the Atp7b -/- knock-out mouse model of Wilson’s disease. Mol Imaging Biol 14:70–78
Bahde R, Kapoor S, Bhargava KK, Palestro CJ, Gupta S (2014) Diagnosis of abnormal biliary copper excretion by positron emission tomography with targeting of 64copper-asialofetuin complex in LEC rat model of Wilson’s disease. Am J Nucl Med Mol Imaging 4:537–547
Wu J, Forbes JR, Chen HS, Cox DW (1994) The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene. Nat Genet 7:541–545
Lutsenko S (2008) Atp7b -/- mice as a model for studies of Wilson’s disease. Biochem Soc Trans 36(Pt 6):1233–1238
Neufeld DS (1997) Isolation of rat liver hepatocytes. Methods Mol Biol 75:145–151
Malhi H, Bhargava KK, Afriyie M, Volenberg I, Schilsky ML, Palestro CJ, Gupta S (2002) 99mTc-mebrofenin scintiscanning for evaluating liver disease in a rat model of Wilson’s disease. J Nucl Med 43:246–252
Schilsky ML, Irani AN, Gorla GR, Volenberg I, Gupta S (2000) Biliary copper excretion capacity in intact animals: correlation between ATP7B function, hepatic mass and copper excretion. J Biochem Mol Toxicol 14:210–214
Acknowledgment
Supported in part by NIH grants, R01-DK088561, R01-DK071111, and P30-DK41296.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Jaber, F.L., Sharma, Y., Gupta, S. (2017). Demonstrating Potential of Cell Therapy for Wilson’s Disease with the Long-Evans Cinnamon Rat Model. In: Stock, P., Christ, B. (eds) Hepatocyte Transplantation. Methods in Molecular Biology, vol 1506. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6506-9_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6506-9_11
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6504-5
Online ISBN: 978-1-4939-6506-9
eBook Packages: Springer Protocols